New allergy drug aims to lower IgE levels in early trial
NCT ID NCT07408869
First seen Feb 19, 2026 · Last updated May 20, 2026 · Updated 11 times
Summary
This early-stage study tests a new drug, cizutamig, in about 20 people with IgE-mediated allergies, such as food allergies or allergic rhinitis. The main goal is to see if the drug can safely lower IgE levels in the blood. Researchers will also monitor side effects and how the drug moves through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGE-MEDIATED COW MILK ALLERGY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nucleus Network
Melbourne, Victoria, 3004, Australia
Contact
Conditions
Explore the condition pages connected to this study.